Seite 1 von 2
Literaturverzeichnis
zum Titelthema „Dermatologie – highlighted“
von Professor Dr. (Univ. Genf) Lars French, Privatdozent Dr. Michael Flaig, Dr. Kinan Hayani, Dr. Markus Heppt, Dr. Laura Engels, Privatdozent Dr. Max Schlaak, Nora Aszodi und
Professor Dr. Dr. h.c. Andreas Wollenberg Bayerisches Ärzteblatt 10/2019, Seite 488 ff.
1. Lebargy F,Wolkenstein P, GisselbrechtM, Lange F, Fleury-Feith J, Delclaux C, Roupie E, Revuz J, Roujeau JC. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997 Dec;23(12):1237–1244
2. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, Touraine R. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol.
1987 Sep;123(9):1160–1165
3. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens- Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007 Feb; 26(2):123–129
4. Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z, Hashimoto K, Kinoshita S.
Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009 Apr;116(4):685-90.
5. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of
sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986 Aug;105(2):179–184 6. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P,
BagotM A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics. 1995 Aug;5(4):255–258 7. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH,
Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998 Oct;282(5388):490–493).
8. Hoetzenecker W, Nägeli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, Guenova E, Cozzio A, French LE. Adverse cutaneous drug eruptions: current
understanding.Semin Immunopathol. 2016 Jan;38(1):75-86.
9. Hosaka H, Ohtoshi S, Nakada T, Iijima M. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen section diagnosis. J Dermatol 2010 May;37:407-12.).
10. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.
Arch Dermatol 1993 Jan;129:92-6.
11. Schneider JA, Cohen PR. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv Ther. 2017 Jun;34(6):1235-1244
12. Ye LP, Zhang C, Zhu QX. The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis. PLoS One. 2016 Nov 30;11(11)
13. Micheletti, R. G., Chiesa-Fuxench, Z., Noe, M. H., Stephen, S., Aleshin, M., Agarwal, A., Rosenbach, M. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J Invest Dermatol. 2018 Nov;138(11):2315-2321
14. J Immunother. 2019 May 15
Lesage C et al. Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
15. Dtsch. Ärzteblatt Int. 2019 Feb 22;116(8):119-126. doi: 10.3238/arztebl.2019.0119.
Heinzerling L1, de Toni EN, Schett G, Hundorfean G, Zimmer L. Checkpoint Inhibitors.
16. Wollenberg, A., et al., ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol, 2016. 30(5): p. 729-47.
17. Werfel, T., et al., [Atopic dermatitis: S2 guidelines]. J Dtsch Dermatol Ges, 2009. 7 Suppl 1: p.
S1-46.
Seite 2 von 2
18. Wollenberg, A., et al., Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol, 2018. 32(6):
p. 850-878.
19. Seegräber, M., et al., Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol, 2018: p. 1-8.
20. Werfel, T., et al., Neues in der Systemtherapie der atopischen Dermatitis. Der Hautarzt, 2018.
69(3): p. 217-224.
21. Wollenberg, A., et al., Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract, 2018.
22. Wohlrab, J., et al., Interdisziplinäre Handlungsempfehlung bei Dupilumab-assoziierten entzündlichen Augenerkrankungen. Der Hautarzt, 2019. 70(1): p. 64-67.
23. Adaptiert nach Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K;
ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct. 1;29
